Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Common Share

Net Loss per Common Share

9 Months Ended

Sep. 30, 2017

14. Net Loss per Common Share

Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock and common stock equivalents outstanding for the period.

The Company’s common stock equivalents, including unvested restricted stock, options, and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted net loss per share is the same.

The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive at the end of the nine months ended September 30, 2017 and 2016:

	Nine Months Ended September 30,
	2017		2016
Warrants to purchase Common Stock		678,072		480,559
Opus warrants to purchase Common Stock		206,593		1,700,000
Options to purchase Common Stock		1,095,905		1,769,426
Unvested Restricted Stock		9,848,505		8,763,797
Unvested Restricted Stock Units		1,234,555		1,054,091
Total		13,063,630		13,767,873